Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health
Bethesda, United States
Jing Wu MD., PhD is an investigator and clinical neuro-oncologist at Neuro-oncology Branch, National Cancer Institute, National Institutes of Health. Dr. Wu received her MD degree from Capital Medical University in Beijing, China and Ph.D. in neuroscience from the University of Texas. She subsequently completed an NIH postdoctoral fellowship under William D. Willis, who was a significant contributor to the fields of pain and neuroscience. Following her Ph.D., she completed a neurology residency at The University of Texas Health Science Center (where she also served as the chief resident), and a Neuro-Oncology fellowship at The University of Texas MD Anderson Cancer Center. She then joined the University of North Carolina (UNC) at Chapel Hill as a tenure-track assistant professor in the Department of Neurosurgery and Neurology. She served as the co-director of the Brain Tumor Program at the Lineberger Comprehensive Cancer Center and developed a clinical and translational research program in neuro-oncology at UNC. Dr. Wu joined the NCI Center for Cancer Research in 2015 as a staff physician, and soon became the director of the Neuro-Oncology Fellowship Program as well as a tenure-track investigator overseeing multiple clinical trials.
Dr. Wu is certified both by the American Board of Psychiatry and Neurology (ABPN) in neurology and the United Council for Neurologic Subspecialties (UCNS) in neuro-oncology. She has published over 70 peer-reviewed articles while also serving as an invited reviewer for several prestigious journals and study sections. She has received impressive awards over her training and clinical tenure, including the William James Miller Endowed Fellowship Award in Neuro-Oncology and the NIH/NCI Paul Calabresi Clinical Oncology Scholar Award. In 2018, she was awarded the NIH-Lasker Clinical Research Scholar Award—a prestigious opportunity that provides funding and support for exceptional clinical researchers to develop their clinical translational research programs.